ScienceDex / Researcher record
Kenneth Schultz
- Trethera Corporation (no department on record)
From the FY2024 NIH awards this investigator leads as contact PI. The department is the award's.
FY2024 NIH rank #2,670
Start your CV
Start from a Word CV, PubMed IDs or ORCID.
- Early Career
- Diverse Portfolio
NIH Funding · FY2024
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
Linked awards ($M)Award-linked rank
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $2,965,289 | 5 | #2,670 |
| 2025 | $5,079,216 | 6 | #1,367 |
| 2026 | $3,042,243 | 3 | #6,079 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY2024 · selected5 records
- FY20256 records
- FY20263 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 77812017Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2024 award records by amount
NIH award records listing Kenneth Schultz as a PI. Multi-PI records show the full award amount for context.
- 1R44AI186534-01R44Contact PIDevelopment of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)$1.1Maward amount
- 5R44CA281485-02R44Contact PIDevelopment of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types$696.6Kaward amount
- 4R42EY034397-02R42Contact PIDevelopment of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis$615.9Kaward amount
- 5R41AI179213-02R41Contact PIDevelopment of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus$305.7Kaward amount
- 5R41AI179191-02R41Contact PIDevelopment of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)$297.1Kaward amount
Award organization
Organizations that administered FY2024 awards listing Kenneth Schultz as a PI.
FY2024 award administered by Trethera Corporation (CA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardTrethera Corporation
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #2670
- 2024Entered Top 25% NationallyRanked #2670
- 2025$5M Cumulative Funding
- 2025Entered Top 10% NationallyRanked #1367
- 2026$10M Cumulative Funding